SAVA - Cassava Sciences again under scrutiny over Alzheimer's drug research
2024-03-11 19:15:08 ET
A lab run a City University of New York (CUNY) scientist with ties to Cassava Sciences ( NASDAQ: SAVA ) and its Alzheimer's candidate simufilam was flagged with a multitude of issues during a September 2022 US FDA inspection....
Cassava Sciences again under scrutiny over Alzheimer's drug research